JP2019533475A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019533475A5 JP2019533475A5 JP2019531513A JP2019531513A JP2019533475A5 JP 2019533475 A5 JP2019533475 A5 JP 2019533475A5 JP 2019531513 A JP2019531513 A JP 2019531513A JP 2019531513 A JP2019531513 A JP 2019531513A JP 2019533475 A5 JP2019533475 A5 JP 2019533475A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- cdr
- bispecific antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 64
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims description 34
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims description 34
- 238000000034 method Methods 0.000 claims description 27
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 24
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 24
- 102000004169 proteins and genes Human genes 0.000 claims description 24
- 108090000623 proteins and genes Proteins 0.000 claims description 24
- 108060003951 Immunoglobulin Proteins 0.000 claims description 22
- 102000018358 immunoglobulin Human genes 0.000 claims description 22
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 18
- 150000007523 nucleic acids Chemical class 0.000 claims description 16
- 206010028980 Neoplasm Diseases 0.000 claims description 15
- 206010062016 Immunosuppression Diseases 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 12
- 230000000694 effects Effects 0.000 claims description 12
- 230000001506 immunosuppresive effect Effects 0.000 claims description 12
- 108020004707 nucleic acids Proteins 0.000 claims description 12
- 102000039446 nucleic acids Human genes 0.000 claims description 12
- 239000000126 substance Substances 0.000 claims description 10
- 229940079593 drug Drugs 0.000 claims description 9
- 230000000903 blocking effect Effects 0.000 claims description 8
- 230000002222 downregulating effect Effects 0.000 claims description 8
- 206010005003 Bladder cancer Diseases 0.000 claims description 6
- 206010009944 Colon cancer Diseases 0.000 claims description 6
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 6
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 claims description 6
- 102100037850 Interferon gamma Human genes 0.000 claims description 6
- 108010074328 Interferon-gamma Proteins 0.000 claims description 6
- 102000000588 Interleukin-2 Human genes 0.000 claims description 6
- 108010002350 Interleukin-2 Proteins 0.000 claims description 6
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 6
- 206010033128 Ovarian cancer Diseases 0.000 claims description 6
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 6
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims description 6
- 206010060862 Prostate cancer Diseases 0.000 claims description 6
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 6
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 6
- 208000007502 anemia Diseases 0.000 claims description 6
- 210000004027 cell Anatomy 0.000 claims description 6
- 239000012634 fragment Substances 0.000 claims description 6
- 208000032839 leukemia Diseases 0.000 claims description 6
- 201000007270 liver cancer Diseases 0.000 claims description 6
- 208000014018 liver neoplasm Diseases 0.000 claims description 6
- 201000001441 melanoma Diseases 0.000 claims description 6
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 6
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 5
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
- 102000004190 Enzymes Human genes 0.000 claims description 4
- 108090000790 Enzymes Proteins 0.000 claims description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 4
- 230000008685 targeting Effects 0.000 claims description 4
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 210000004798 organs belonging to the digestive system Anatomy 0.000 claims description 3
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 2
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims description 2
- 101000998953 Homo sapiens Immunoglobulin heavy variable 1-2 Proteins 0.000 claims description 2
- 102100036887 Immunoglobulin heavy variable 1-2 Human genes 0.000 claims description 2
- 241000283984 Rodentia Species 0.000 claims description 2
- 230000003213 activating effect Effects 0.000 claims description 2
- 239000000427 antigen Substances 0.000 claims description 2
- 102000036639 antigens Human genes 0.000 claims description 2
- 108091007433 antigens Proteins 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 230000009977 dual effect Effects 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 238000001727 in vivo Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 241000894007 species Species 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 6
- 238000003745 diagnosis Methods 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022089567A JP2022130393A (ja) | 2016-08-23 | 2022-06-01 | 抗ｃｔｌａ４－抗ｐｄ－１二機能性抗体、その医薬組成物および使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610705624.2A CN106967172B (zh) | 2016-08-23 | 2016-08-23 | 抗ctla4-抗pd-1 双功能抗体、其药物组合物及其用途 |
| CN201610705624.2 | 2016-08-23 | ||
| PCT/CN2017/098466 WO2018036473A1 (zh) | 2016-08-23 | 2017-08-22 | 抗ctla4-抗pd-1双功能抗体、其药物组合物及其用途 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022089567A Division JP2022130393A (ja) | 2016-08-23 | 2022-06-01 | 抗ｃｔｌａ４－抗ｐｄ－１二機能性抗体、その医薬組成物および使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019533475A JP2019533475A (ja) | 2019-11-21 |
| JP2019533475A5 true JP2019533475A5 (OSRAM) | 2020-07-16 |
| JP7425604B2 JP7425604B2 (ja) | 2024-01-31 |
Family
ID=59334390
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019531513A Active JP7425604B2 (ja) | 2016-08-23 | 2017-08-22 | 抗ｃｔｌａ４－抗ｐｄ－１二機能性抗体、その医薬組成物および使用 |
| JP2022089567A Pending JP2022130393A (ja) | 2016-08-23 | 2022-06-01 | 抗ｃｔｌａ４－抗ｐｄ－１二機能性抗体、その医薬組成物および使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022089567A Pending JP2022130393A (ja) | 2016-08-23 | 2022-06-01 | 抗ｃｔｌａ４－抗ｐｄ－１二機能性抗体、その医薬組成物および使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11578128B2 (OSRAM) |
| EP (1) | EP3511346A4 (OSRAM) |
| JP (2) | JP7425604B2 (OSRAM) |
| KR (1) | KR102503084B1 (OSRAM) |
| CN (1) | CN106967172B (OSRAM) |
| AU (1) | AU2017317124B2 (OSRAM) |
| BR (1) | BR112019003695A2 (OSRAM) |
| CA (1) | CA3034850A1 (OSRAM) |
| EA (1) | EA201990571A1 (OSRAM) |
| IL (1) | IL264964B2 (OSRAM) |
| MX (1) | MX2019002254A (OSRAM) |
| NZ (2) | NZ751904A (OSRAM) |
| SG (1) | SG11201901583WA (OSRAM) |
| WO (1) | WO2018036473A1 (OSRAM) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7014706B2 (ja) | 2015-07-13 | 2022-02-01 | サイトメックス セラピューティクス インコーポレイテッド | 抗ｐｄ－１抗体、活性化可能抗ｐｄ－１抗体、およびその使用方法 |
| US10787518B2 (en) | 2016-06-14 | 2020-09-29 | Xencor, Inc. | Bispecific checkpoint inhibitor antibodies |
| CN106977602B (zh) * | 2016-08-23 | 2018-09-25 | 中山康方生物医药有限公司 | 一种抗pd1单克隆抗体、其药物组合物及其用途 |
| CN106967172B (zh) | 2016-08-23 | 2019-01-08 | 康方药业有限公司 | 抗ctla4-抗pd-1 双功能抗体、其药物组合物及其用途 |
| WO2018035710A1 (en) | 2016-08-23 | 2018-03-01 | Akeso Biopharma, Inc. | Anti-ctla4 antibodies |
| CN108866635B (zh) * | 2017-05-09 | 2021-11-26 | 安升（上海）医药科技有限公司 | 多特异性蛋白药物及其文库、以及制备方法和应用 |
| EP3626745A4 (en) | 2017-09-01 | 2021-03-17 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | RECOMBINANT BISPECIFIC ANTIBODY |
| CA3069238A1 (en) * | 2017-11-02 | 2019-05-09 | Systimmune, Inc. | Bispecific antibodies and methods of making and using thereof |
| WO2019179421A1 (en) * | 2018-03-19 | 2019-09-26 | Wuxi Biologics (Shanghai) Co., Ltd. | Novel bispecific pd-1/ctla-4 antibody molecules |
| CN110407942B (zh) * | 2018-04-27 | 2022-02-22 | 苏州康宁杰瑞生物科技有限公司 | 针对kn044的单域抗体 |
| JP7359785B2 (ja) * | 2018-06-05 | 2023-10-11 | 江蘇康寧杰瑞生物制薬有限公司 | 二量体及びその使用 |
| CN110684113A (zh) * | 2018-07-06 | 2020-01-14 | 复旦大学 | 一种抗PD-1抗原和抗c-Met抗原的双特异性抗体及其构建方法 |
| CN109762068A (zh) * | 2018-08-09 | 2019-05-17 | 源道隆（苏州）医学科技有限公司 | 一种可靶向ctla4和pd-1的单基因双特异性抗体及其应用 |
| CN109053895B (zh) | 2018-08-30 | 2020-06-09 | 中山康方生物医药有限公司 | 抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途 |
| WO2020057611A1 (en) * | 2018-09-20 | 2020-03-26 | Wuxi Biologics (Shanghai) Co., Ltd. | Novel bispecific ctla-4/pd-1 polypeptide complexes |
| WO2020057610A1 (en) * | 2018-09-20 | 2020-03-26 | Wuxi Biologics (Shanghai) Co., Ltd. | Novel bispecific anti-ctla-4/pd-1 polypeptide complexes |
| CN111763261B (zh) * | 2019-04-02 | 2022-08-09 | 杭州尚健生物技术有限公司 | 一种融合蛋白及其用途 |
| CN112175087B (zh) * | 2019-07-02 | 2022-05-13 | 深圳市迈加瑞生物技术有限公司 | 一种抗CD4和TGFβ的双特异性抗体、其药物组合及其用途 |
| EP3998286A4 (en) * | 2019-07-11 | 2023-04-26 | Wuhan Yzy Biopharma Co., Ltd. | Tetravalent symmetric bispecific antibody |
| MX2022001321A (es) * | 2019-08-02 | 2022-05-20 | Akeso Pharmaceuticals Inc | Anticuerpo biespecifico anti-ctla4/anti-pd-1 y uso del mismo. |
| CA3146777A1 (en) * | 2019-08-02 | 2021-02-11 | CTTQ-Akeso (ShangHai) Biomed. Tech. Co., Ltd. | Anti-pd-1 antibody and pharmaceutical use thereof |
| CN112442126B (zh) | 2019-09-04 | 2022-07-29 | 杭州济元基因科技有限公司 | 一种抗人cs1抗原的单克隆抗体及其car-t细胞 |
| CN110563845A (zh) * | 2019-09-12 | 2019-12-13 | 滨州医学院 | 抗igsf9抗体、药物组合物及其应用 |
| IL293241A (en) | 2019-11-25 | 2022-07-01 | Akeso Biopharma Inc | Bispecific antibody, anti-1-pd, anti-vegfa, pharmaceutical preparation containing it and its use |
| CN114746448A (zh) * | 2019-12-04 | 2022-07-12 | 江苏康宁杰瑞生物制药有限公司 | 用于肿瘤治疗的双特异性融合蛋白 |
| KR20230004726A (ko) * | 2020-04-22 | 2023-01-06 | 아케소 바이오파마, 인크. | 항-cd73/항-pd-1 이중특이항체 및 이의 용도 |
| WO2021213523A1 (zh) * | 2020-04-24 | 2021-10-28 | 信达生物制药(苏州)有限公司 | 抗pd-1抗体和抗ctla-4抗体的组合在预防或治疗癌症中的用途 |
| BR112022022020A2 (pt) * | 2020-04-29 | 2023-01-31 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | Proteína bifuncional contra pd-1 e tgf-ss |
| CN113577255B (zh) * | 2020-04-30 | 2023-09-08 | 中国科学院上海药物研究所 | 肿瘤纳米疫苗、其制备方法及用途 |
| CN113754767A (zh) * | 2020-06-03 | 2021-12-07 | 上海恒润达生生物科技股份有限公司 | 抗人pd-1抗体及其用途 |
| MX2023001111A (es) * | 2020-07-27 | 2023-03-07 | Macrogenics Inc | Metodo para el uso de una molecula pd-1 x ctla-4 biespecifica. |
| CN111944760A (zh) * | 2020-08-14 | 2020-11-17 | 广东先康达生物科技有限公司 | 一种分泌双特异性抗体的免疫细胞及其应用 |
| CN112079926A (zh) * | 2020-09-17 | 2020-12-15 | 北京华大蛋白质研发中心有限公司 | 抗人ctla4单克隆抗体及其应用 |
| IL302182A (en) * | 2020-10-23 | 2023-06-01 | Akeso Biopharma Inc | Anti-CD73 antibody and its use |
| EP4190819A4 (en) | 2021-03-12 | 2024-08-14 | Akeso Biopharma, Inc. | PHARMACEUTICAL COMBINATION CONTAINING BISPECIFIC ANTI-PD-1-ANTI-VEGFA ANTIBODY, AND USE THEREOF |
| CN118530342A (zh) * | 2021-03-12 | 2024-08-23 | 中山康方生物医药有限公司 | 降低免疫细胞分泌il-8和/或il-6的水平的方法 |
| CA3213734A1 (en) * | 2021-04-14 | 2022-10-20 | Yu Xia | Use of antibody in anti-tumor treatment |
| CN113501879B (zh) * | 2021-06-30 | 2022-09-06 | 拜盖特生物科技(上海)有限公司 | 一种解除肿瘤免疫微环境中免疫抑制的双功能抗体及其应用和制备方法 |
| KR20240038043A (ko) * | 2021-07-23 | 2024-03-22 | 아케소 바이오파마, 인크. | 약학적 조성물 및 용도 |
| MX2024003936A (es) | 2021-09-29 | 2024-06-28 | Akeso Biopharma Inc | Anticuerpo anti-lag3, composicion farmaceutica y uso. |
| CN118541390A (zh) * | 2022-01-30 | 2024-08-23 | 百奥赛图(北京)医药科技股份有限公司 | 抗ctla4/ox40双特异性抗体及其用途 |
| EP4483877A1 (en) | 2022-02-24 | 2025-01-01 | Akeso Pharmaceuticals, Inc. | Pharmaceutical composition comprising anti-ctla4-anti-pd-1 bispecific antibody and chiauranib |
| JP2025530041A (ja) * | 2022-09-09 | 2025-09-11 | 中山康方生物医▲藥▼有限公司 | 治療用組合せ物とその使用 |
| CN117679505A (zh) | 2022-09-09 | 2024-03-12 | 中山康方生物医药有限公司 | 药物组合及用途 |
| CN116396392B (zh) * | 2023-01-17 | 2023-10-27 | 珠海重链生物科技有限公司 | 一种特异性针对异羟基洋地黄毒甙元的抗体及其相关应用 |
| WO2024183791A1 (zh) * | 2023-03-07 | 2024-09-12 | 康方药业有限公司 | 包含抗ctla4-抗pd-1双特异性抗体的药物组合及其用途 |
| WO2024212988A1 (zh) | 2023-04-10 | 2024-10-17 | 康方药业有限公司 | 抗ctla4-抗pd-1双特异性抗体的医药用途 |
| CN120361206A (zh) * | 2024-01-25 | 2025-07-25 | 中山康方生物医药有限公司 | 抗pd-1-抗vegfa的双特异性抗体的医药用途 |
| CN120714022A (zh) * | 2024-03-27 | 2025-09-30 | 康方汇科(上海)生物有限公司 | 药物组合及用途 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US7595048B2 (en) | 2002-07-03 | 2009-09-29 | Ono Pharmaceutical Co., Ltd. | Method for treatment of cancer by inhibiting the immunosuppressive signal induced by PD-1 |
| WO2004056875A1 (en) | 2002-12-23 | 2004-07-08 | Wyeth | Antibodies against pd-1 and uses therefor |
| CA2722466A1 (en) | 2008-04-29 | 2009-11-05 | Tariq Ghayur | Dual variable domain immunoglobulins and uses thereof |
| US20100260668A1 (en) * | 2008-04-29 | 2010-10-14 | Abbott Laboratories | Dual Variable Domain Immunoglobulins and Uses Thereof |
| MX2011003195A (es) | 2008-09-26 | 2011-08-12 | Dana Farber Cancer Inst Inc | Anticuerpos anti-pd-1, pd-l1 y pd-l2 humanos y usos de los mismos. |
| EP2545073B1 (en) | 2010-03-12 | 2015-09-30 | AbbVie Biotherapeutics Inc. | Ctla4 proteins and their uses |
| GB201103955D0 (en) | 2011-03-09 | 2011-04-20 | Antitope Ltd | Antibodies |
| RU2563346C2 (ru) | 2011-03-31 | 2015-09-20 | Мерк Шарп И Доум Корп. | Стабильные составы антител против рецептора программируемой смерти pd-1 человека и относящиеся к ним способы лечения |
| CA2833636A1 (en) | 2011-04-20 | 2012-10-26 | Amplimmune, Inc. | Antibodies and other molecules that bind b7-h1 and pd-1 |
| WO2014022758A1 (en) | 2012-08-03 | 2014-02-06 | Dana-Farber Cancer Institute, Inc. | Single agent anti-pd-l1 and pd-l2 dual binding antibodies and methods of use |
| WO2014209804A1 (en) * | 2013-06-24 | 2014-12-31 | Biomed Valley Discoveries, Inc. | Bispecific antibodies |
| CN104250302B (zh) | 2013-06-26 | 2017-11-14 | 上海君实生物医药科技股份有限公司 | 抗pd‑1抗体及其应用 |
| EP4285928A3 (en) | 2013-09-27 | 2024-03-13 | F. Hoffmann-La Roche AG | Anti-pdl1 antibody formulations |
| SG11201604738TA (en) | 2013-12-12 | 2016-07-28 | Shanghai Hengrui Pharm Co Ltd | Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof |
| RU2694981C2 (ru) | 2014-01-03 | 2019-07-18 | Ф. Хоффманн-Ля Рош Аг | Ковалентно связанные конъюгаты хеликар-антитело против хеликара и их применения |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| CN104974253A (zh) * | 2014-04-01 | 2015-10-14 | 上海中信国健药业股份有限公司 | 抗ctla-4/pd-1双特异性抗体、其制备方法及应用 |
| CN105296433B (zh) * | 2014-08-01 | 2018-02-09 | 中山康方生物医药有限公司 | 一种ctla4抗体、其药物组合物及其用途 |
| CN104987421A (zh) | 2015-05-13 | 2015-10-21 | 北京比洋生物技术有限公司 | 抗ctla-4和pd-1的双重可变结构域免疫球蛋白 |
| CN105175545B (zh) | 2015-10-20 | 2019-01-25 | 安徽瀚海博兴生物技术有限公司 | 一种抗vegf-抗pd-1双功能抗体及其应用 |
| CN105175544B (zh) * | 2015-10-20 | 2021-04-09 | 安徽瀚海博兴生物技术有限公司 | 一种抗pd-1人源化单克隆抗体及其应用 |
| SG11201804839WA (en) * | 2015-12-14 | 2018-07-30 | Macrogenics Inc | Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof |
| CN105754990A (zh) | 2016-01-29 | 2016-07-13 | 深圳精准医疗科技有限公司 | 一种pd-1/ctla-4双特异性抗体的制备方法及其应用 |
| CN106977602B (zh) | 2016-08-23 | 2018-09-25 | 中山康方生物医药有限公司 | 一种抗pd1单克隆抗体、其药物组合物及其用途 |
| WO2018035710A1 (en) | 2016-08-23 | 2018-03-01 | Akeso Biopharma, Inc. | Anti-ctla4 antibodies |
| CN106967172B (zh) | 2016-08-23 | 2019-01-08 | 康方药业有限公司 | 抗ctla4-抗pd-1 双功能抗体、其药物组合物及其用途 |
| MX2022001321A (es) | 2019-08-02 | 2022-05-20 | Akeso Pharmaceuticals Inc | Anticuerpo biespecifico anti-ctla4/anti-pd-1 y uso del mismo. |
-
2016
- 2016-08-23 CN CN201610705624.2A patent/CN106967172B/zh active Active
-
2017
- 2017-08-22 KR KR1020197008463A patent/KR102503084B1/ko active Active
- 2017-08-22 EA EA201990571A patent/EA201990571A1/ru unknown
- 2017-08-22 US US16/327,076 patent/US11578128B2/en active Active
- 2017-08-22 SG SG11201901583WA patent/SG11201901583WA/en unknown
- 2017-08-22 NZ NZ751904A patent/NZ751904A/en unknown
- 2017-08-22 CA CA3034850A patent/CA3034850A1/en active Pending
- 2017-08-22 NZ NZ791621A patent/NZ791621A/en unknown
- 2017-08-22 IL IL264964A patent/IL264964B2/en unknown
- 2017-08-22 BR BR112019003695-4A patent/BR112019003695A2/pt unknown
- 2017-08-22 JP JP2019531513A patent/JP7425604B2/ja active Active
- 2017-08-22 MX MX2019002254A patent/MX2019002254A/es unknown
- 2017-08-22 EP EP17842896.7A patent/EP3511346A4/en active Pending
- 2017-08-22 WO PCT/CN2017/098466 patent/WO2018036473A1/zh not_active Ceased
- 2017-08-22 AU AU2017317124A patent/AU2017317124B2/en active Active
-
2022
- 2022-06-01 JP JP2022089567A patent/JP2022130393A/ja active Pending
- 2022-12-16 US US18/067,669 patent/US12479919B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019533475A5 (OSRAM) | ||
| JP2019534034A5 (OSRAM) | ||
| ES2595091T3 (es) | Composiciones farmacéuticas con resistencia a CEA soluble | |
| CN112111008B (zh) | 抗cd73抗体及其应用 | |
| CN101687021B (zh) | 单克隆抗体8h9的应用 | |
| ES2616316T3 (es) | Composiciones que comprenden anticuerpos específicos para diferentes especies y usos de los mismos | |
| JP2021502810A5 (OSRAM) | ||
| JP2013502913A5 (OSRAM) | ||
| JP2018512175A5 (OSRAM) | ||
| JP2019531697A5 (OSRAM) | ||
| Hong et al. | Chemoenzymatic Synthesis of a Rhamnose‐Functionalized Bispecific Nanobody as a Bispecific Antibody Mimic for Cancer Immunotherapy | |
| CN117946278A (zh) | 多特异性抗体及其制备和使用方法 | |
| JP2019512207A5 (OSRAM) | ||
| WO2017025033A1 (zh) | 用于治疗cea阳性表达肿瘤的双特异纳米抗体 | |
| JP2018528759A5 (OSRAM) | ||
| WO2023071676A1 (zh) | 一种抗her2/抗pd-l1双功能抗体及其应用 | |
| WO2021163097A1 (en) | Tandem repeat cancer-targeting peptides for molecular conjugation or engineering and uses thereof in cancer theranostics | |
| CN114786720B (zh) | TriAx抗体的组合物及其制备和使用方法 | |
| JP2009544574A5 (OSRAM) | ||
| JP2024541175A (ja) | Ｈｅｒｖ－ｋ抗体治療法 | |
| EP4387998A1 (en) | Antibodies and antigen binding fragments against cd155 methods of use thereof | |
| JPWO2020191342A5 (OSRAM) | ||
| JP7695272B2 (ja) | 抗ｃｔｌａ４モノクローナル抗体及びキメラ抗原受容体 | |
| KR20240127523A (ko) | 항-cntn4 항체 및 그의 용도 | |
| JP7378088B2 (ja) | ｈＥＲＧ１およびｈＥＲＧ１／インテグリンβ１に結合する単一特異性および二重特異性抗体 |